Diabetic Nephropathy and Extracellular Matrix

Diabetic nephropathy (DN) is a serious complication in diabetes. Major typical morphological changes are the result of changes in the extracellular matrix (ECM). Thus, basement membranes are thickened and the glomerular mesangial matrix and the tubulointerstitial space are expanded, due to increased...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of histochemistry and cytochemistry 2012-12, Vol.60 (12), p.976-986
Hauptverfasser: Kolset, S. O., Reinholt, F. P., Jenssen, T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 986
container_issue 12
container_start_page 976
container_title The journal of histochemistry and cytochemistry
container_volume 60
creator Kolset, S. O.
Reinholt, F. P.
Jenssen, T.
description Diabetic nephropathy (DN) is a serious complication in diabetes. Major typical morphological changes are the result of changes in the extracellular matrix (ECM). Thus, basement membranes are thickened and the glomerular mesangial matrix and the tubulointerstitial space are expanded, due to increased amounts of ECM. One important ECM component, the proteoglycans (PGs), shows a more complex pattern of changes in DN. PGs in basement membranes are decreased but increased in the mesangium and the tubulointerstitial space. The amounts and structures of heparan sulfate chains are changed, and such changes affect levels of growth factors regulating cell proliferation and ECM synthesis, with cell attachment affecting endothelial cells and podocytes. Enzymes modulating heparan sulfate structures, such as heparanase and sulfatases, are implicated in DN. Other enzyme classes also modulate ECM proteins and PGs, such as matrix metalloproteinases (MMPs) and serine proteases, such as plasminogen activator, as well as their corresponding inhibitors. The levels of these enzymes and inhibitors are changed in plasma and in the kidneys in DN. Several growth factors, signaling pathways, and hyperglycemia per se affect ECM synthesis and turnover in DN. Whether ECM components can be used as markers for early kidney changes is an important research topic, whereas at present, the clinical use remains to be established.
doi_str_mv 10.1369/0022155412465073
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3527883</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1369_0022155412465073</sage_id><sourcerecordid>1221131543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-1b14e636f8acd3f10af48082cf13531aed87d2c2f17b252a7c1a4a853fe33a243</originalsourceid><addsrcrecordid>eNp1kM1PwzAMxSMEYmNw54R25FKI89GGCxIa40MacIFz5KbJ1qlrS9Ki7b-n1QYCJE6W9Z6f7R8hp0AvgMdXl5QyBlIKYCKWNOF7ZNi1EEkqxD4Z9nLU6wNyFMKSUhBCqkMyYBwoTxgfkug2x9Q2uRk_23rhqxqbxWaMZTaerhuPxhZFW6AfP2Hj8_UxOXBYBHuyqyPydjd9nTxEs5f7x8nNLDKS0iaCFISNeewUmow7oOiEoooZB1xyQJupJGOGOUhSJhkmBlCgktxZzpEJPiLX29y6TVc2M7bsbil07fMV-o2uMNe_lTJf6Hn1oblkiVK8CzjfBfjqvbWh0as89M9gaas2aOi4AQcpeivdWo2vQvDWfa8BqnvK-i_lbuTs53nfA19YO0O0NQScW72sWl92uP4P_AQnfoP9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1221131543</pqid></control><display><type>article</type><title>Diabetic Nephropathy and Extracellular Matrix</title><source>Access via SAGE</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Kolset, S. O. ; Reinholt, F. P. ; Jenssen, T.</creator><creatorcontrib>Kolset, S. O. ; Reinholt, F. P. ; Jenssen, T.</creatorcontrib><description>Diabetic nephropathy (DN) is a serious complication in diabetes. Major typical morphological changes are the result of changes in the extracellular matrix (ECM). Thus, basement membranes are thickened and the glomerular mesangial matrix and the tubulointerstitial space are expanded, due to increased amounts of ECM. One important ECM component, the proteoglycans (PGs), shows a more complex pattern of changes in DN. PGs in basement membranes are decreased but increased in the mesangium and the tubulointerstitial space. The amounts and structures of heparan sulfate chains are changed, and such changes affect levels of growth factors regulating cell proliferation and ECM synthesis, with cell attachment affecting endothelial cells and podocytes. Enzymes modulating heparan sulfate structures, such as heparanase and sulfatases, are implicated in DN. Other enzyme classes also modulate ECM proteins and PGs, such as matrix metalloproteinases (MMPs) and serine proteases, such as plasminogen activator, as well as their corresponding inhibitors. The levels of these enzymes and inhibitors are changed in plasma and in the kidneys in DN. Several growth factors, signaling pathways, and hyperglycemia per se affect ECM synthesis and turnover in DN. Whether ECM components can be used as markers for early kidney changes is an important research topic, whereas at present, the clinical use remains to be established.</description><identifier>ISSN: 0022-1554</identifier><identifier>EISSN: 1551-5044</identifier><identifier>DOI: 10.1369/0022155412465073</identifier><identifier>PMID: 23103723</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Animals ; Chondroitin Sulfates - metabolism ; Dermatan Sulfate - metabolism ; Diabetic Neuropathies - metabolism ; Diabetic Neuropathies - physiopathology ; Diabetic Neuropathies - therapy ; Extracellular Matrix - metabolism ; Glycocalyx - pathology ; Heparan Sulfate Proteoglycans - metabolism ; Humans ; Kidney - metabolism ; Kidney - pathology ; Kidney - physiopathology ; Matrix Metalloproteinases - metabolism ; Proteoglycans - metabolism ; Signal Transduction</subject><ispartof>The journal of histochemistry and cytochemistry, 2012-12, Vol.60 (12), p.976-986</ispartof><rights>The Author(s) 2012</rights><rights>The Author(s) 2012 2012 The Histochemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-1b14e636f8acd3f10af48082cf13531aed87d2c2f17b252a7c1a4a853fe33a243</citedby><cites>FETCH-LOGICAL-c500t-1b14e636f8acd3f10af48082cf13531aed87d2c2f17b252a7c1a4a853fe33a243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1369/0022155412465073$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1369/0022155412465073$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>230,314,780,784,885,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23103723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kolset, S. O.</creatorcontrib><creatorcontrib>Reinholt, F. P.</creatorcontrib><creatorcontrib>Jenssen, T.</creatorcontrib><title>Diabetic Nephropathy and Extracellular Matrix</title><title>The journal of histochemistry and cytochemistry</title><addtitle>J Histochem Cytochem</addtitle><description>Diabetic nephropathy (DN) is a serious complication in diabetes. Major typical morphological changes are the result of changes in the extracellular matrix (ECM). Thus, basement membranes are thickened and the glomerular mesangial matrix and the tubulointerstitial space are expanded, due to increased amounts of ECM. One important ECM component, the proteoglycans (PGs), shows a more complex pattern of changes in DN. PGs in basement membranes are decreased but increased in the mesangium and the tubulointerstitial space. The amounts and structures of heparan sulfate chains are changed, and such changes affect levels of growth factors regulating cell proliferation and ECM synthesis, with cell attachment affecting endothelial cells and podocytes. Enzymes modulating heparan sulfate structures, such as heparanase and sulfatases, are implicated in DN. Other enzyme classes also modulate ECM proteins and PGs, such as matrix metalloproteinases (MMPs) and serine proteases, such as plasminogen activator, as well as their corresponding inhibitors. The levels of these enzymes and inhibitors are changed in plasma and in the kidneys in DN. Several growth factors, signaling pathways, and hyperglycemia per se affect ECM synthesis and turnover in DN. Whether ECM components can be used as markers for early kidney changes is an important research topic, whereas at present, the clinical use remains to be established.</description><subject>Animals</subject><subject>Chondroitin Sulfates - metabolism</subject><subject>Dermatan Sulfate - metabolism</subject><subject>Diabetic Neuropathies - metabolism</subject><subject>Diabetic Neuropathies - physiopathology</subject><subject>Diabetic Neuropathies - therapy</subject><subject>Extracellular Matrix - metabolism</subject><subject>Glycocalyx - pathology</subject><subject>Heparan Sulfate Proteoglycans - metabolism</subject><subject>Humans</subject><subject>Kidney - metabolism</subject><subject>Kidney - pathology</subject><subject>Kidney - physiopathology</subject><subject>Matrix Metalloproteinases - metabolism</subject><subject>Proteoglycans - metabolism</subject><subject>Signal Transduction</subject><issn>0022-1554</issn><issn>1551-5044</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1PwzAMxSMEYmNw54R25FKI89GGCxIa40MacIFz5KbJ1qlrS9Ki7b-n1QYCJE6W9Z6f7R8hp0AvgMdXl5QyBlIKYCKWNOF7ZNi1EEkqxD4Z9nLU6wNyFMKSUhBCqkMyYBwoTxgfkug2x9Q2uRk_23rhqxqbxWaMZTaerhuPxhZFW6AfP2Hj8_UxOXBYBHuyqyPydjd9nTxEs5f7x8nNLDKS0iaCFISNeewUmow7oOiEoooZB1xyQJupJGOGOUhSJhkmBlCgktxZzpEJPiLX29y6TVc2M7bsbil07fMV-o2uMNe_lTJf6Hn1oblkiVK8CzjfBfjqvbWh0as89M9gaas2aOi4AQcpeivdWo2vQvDWfa8BqnvK-i_lbuTs53nfA19YO0O0NQScW72sWl92uP4P_AQnfoP9</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Kolset, S. O.</creator><creator>Reinholt, F. P.</creator><creator>Jenssen, T.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20121201</creationdate><title>Diabetic Nephropathy and Extracellular Matrix</title><author>Kolset, S. O. ; Reinholt, F. P. ; Jenssen, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-1b14e636f8acd3f10af48082cf13531aed87d2c2f17b252a7c1a4a853fe33a243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Chondroitin Sulfates - metabolism</topic><topic>Dermatan Sulfate - metabolism</topic><topic>Diabetic Neuropathies - metabolism</topic><topic>Diabetic Neuropathies - physiopathology</topic><topic>Diabetic Neuropathies - therapy</topic><topic>Extracellular Matrix - metabolism</topic><topic>Glycocalyx - pathology</topic><topic>Heparan Sulfate Proteoglycans - metabolism</topic><topic>Humans</topic><topic>Kidney - metabolism</topic><topic>Kidney - pathology</topic><topic>Kidney - physiopathology</topic><topic>Matrix Metalloproteinases - metabolism</topic><topic>Proteoglycans - metabolism</topic><topic>Signal Transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kolset, S. O.</creatorcontrib><creatorcontrib>Reinholt, F. P.</creatorcontrib><creatorcontrib>Jenssen, T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of histochemistry and cytochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kolset, S. O.</au><au>Reinholt, F. P.</au><au>Jenssen, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diabetic Nephropathy and Extracellular Matrix</atitle><jtitle>The journal of histochemistry and cytochemistry</jtitle><addtitle>J Histochem Cytochem</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>60</volume><issue>12</issue><spage>976</spage><epage>986</epage><pages>976-986</pages><issn>0022-1554</issn><eissn>1551-5044</eissn><abstract>Diabetic nephropathy (DN) is a serious complication in diabetes. Major typical morphological changes are the result of changes in the extracellular matrix (ECM). Thus, basement membranes are thickened and the glomerular mesangial matrix and the tubulointerstitial space are expanded, due to increased amounts of ECM. One important ECM component, the proteoglycans (PGs), shows a more complex pattern of changes in DN. PGs in basement membranes are decreased but increased in the mesangium and the tubulointerstitial space. The amounts and structures of heparan sulfate chains are changed, and such changes affect levels of growth factors regulating cell proliferation and ECM synthesis, with cell attachment affecting endothelial cells and podocytes. Enzymes modulating heparan sulfate structures, such as heparanase and sulfatases, are implicated in DN. Other enzyme classes also modulate ECM proteins and PGs, such as matrix metalloproteinases (MMPs) and serine proteases, such as plasminogen activator, as well as their corresponding inhibitors. The levels of these enzymes and inhibitors are changed in plasma and in the kidneys in DN. Several growth factors, signaling pathways, and hyperglycemia per se affect ECM synthesis and turnover in DN. Whether ECM components can be used as markers for early kidney changes is an important research topic, whereas at present, the clinical use remains to be established.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>23103723</pmid><doi>10.1369/0022155412465073</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-1554
ispartof The journal of histochemistry and cytochemistry, 2012-12, Vol.60 (12), p.976-986
issn 0022-1554
1551-5044
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3527883
source Access via SAGE; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry
subjects Animals
Chondroitin Sulfates - metabolism
Dermatan Sulfate - metabolism
Diabetic Neuropathies - metabolism
Diabetic Neuropathies - physiopathology
Diabetic Neuropathies - therapy
Extracellular Matrix - metabolism
Glycocalyx - pathology
Heparan Sulfate Proteoglycans - metabolism
Humans
Kidney - metabolism
Kidney - pathology
Kidney - physiopathology
Matrix Metalloproteinases - metabolism
Proteoglycans - metabolism
Signal Transduction
title Diabetic Nephropathy and Extracellular Matrix
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T14%3A25%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diabetic%20Nephropathy%20and%20Extracellular%20Matrix&rft.jtitle=The%20journal%20of%20histochemistry%20and%20cytochemistry&rft.au=Kolset,%20S.%20O.&rft.date=2012-12-01&rft.volume=60&rft.issue=12&rft.spage=976&rft.epage=986&rft.pages=976-986&rft.issn=0022-1554&rft.eissn=1551-5044&rft_id=info:doi/10.1369/0022155412465073&rft_dat=%3Cproquest_pubme%3E1221131543%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1221131543&rft_id=info:pmid/23103723&rft_sage_id=10.1369_0022155412465073&rfr_iscdi=true